Mycobacterium vaccae vaccine - AnHui Longcom Biologic Pharmacy

Drug Profile

Mycobacterium vaccae vaccine - AnHui Longcom Biologic Pharmacy

Alternative Names: Vaccae

Latest Information Update: 02 Jun 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AnHui Longcom Biologic Pharmacy
  • Class Antituberculars; Tuberculosis vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Tuberculosis

Most Recent Events

  • 31 May 2016 Anhui Longcom Biologic Pharmacy completes a phase III trial for Tuberculosis in China prior to May 2016 (ChiCTR-PRC13003741)
  • 31 Jan 2001 Launched for Tuberculosis in China (IM)
  • 31 Jan 2001 Registered for Tuberculosis in China (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top